Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ALGS

Aligos Therapeutics Inc

6.11

Jul 14 • 03:59PM ET -0.26 (-4.01%)

6.11

Aftermarket • 04:15PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Jul 13, 8:05 AMAligos Therapeutics completes enrollment in Phase 2 B-SUPREME trial of HBV candidate pevifoscorvir sodium

Peers: LITS ABVC BOLD DARE EVAX NNVC TVRD GRCE INMB VERU

| Held by: VTI VXF IWC DFMC DFAS DFAC AVSC DFSU

Scroll to Statements

Index	-
Market Cap	37.78M
Enterprise Value	-12.95M
Income	-90.32M
Sales	4.71M
Book/sh	5.14
Cash/sh	8.90
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	82
IPO	Oct 16, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	8.02
P/B	1.19
P/C	0.69
P/FCF	-
EV/EBITDA	-
EV/Sales	-2.75
Quick Ratio	2.56
Current Ratio	2.56
Debt/Eq	0.14
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-8.70
EPS next Y	-4.48
EPS next Q	-1.09
EPS this Y	-187.66%
EPS next Y	36.37%
EPS next 5Y	-4.92%
EPS past 3/5Y	- -
Sales past 3/5Y	-46.03% -
EPS Y/Y TTM	14.79%
Sales Y/Y TTM	43.88%
EPS Q/Q	-4.80%
Sales Q/Q	809.97%
Earnings	May 07 AMC
EPS/Sales Surpr.	0.15% 1032.00%

Insider Own	22.49%
Insider Trans	0.00%
Inst Own	44.85%
Inst Trans	-0.74%
ROA	-83.92%
ROE	-121.86%
ROIC	-278.36%
Gross Margin	77.00%
Oper. Margin	-2033.39%
Profit Margin	-1919.68%
SMA20	5.73%
SMA50	6.28%
SMA200	-20.91%
Trades

Shs Outstand	5.39M
Shs Float	4.80M
Short Float	11.32%
Short Ratio	1.86
Short Interest	0.54M
52W High	13.69 -55.40%
52W Low	4.80 27.19%
Volatility	11.17% 8.62%
ATR (14)	0.50
RSI (14)	54.08
Beta	2.28
Rel Volume	0.34
Avg Volume	291.99K
Volume	100,133

Perf Week	0.25%
Perf Month	15.62%
Perf Quarter	-29.34%
Perf Half Y	-32.17%
Perf YTD	-34.50%
Perf Year	-29.75%
Perf 3Y	-76.29%
Perf 5Y	-98.39%
Perf 10Y	-
Recom	1.00
Target Price	54.88
Prev Close	6.36
Price	6.11
Change	-4.01%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-26	Initiated	Lake Street	Buy	$45
May-21-26	Initiated	Cantor Fitzgerald	Overweight	$20
Mar-19-26	Resumed	Jefferies	Buy	$48
Aug-18-25	Resumed	H.C. Wainwright	Buy	$50
Aug-19-24	Initiated	H.C. Wainwright	Buy	$75
Jan-06-23	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $3
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$2.50 → $3
Mar-23-22	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $4
Jan-07-22	Downgrade	JP Morgan	Overweight → Neutral	$30 → $12
Jan-06-22	Downgrade	Jefferies	Buy → Hold
Sep-09-21	Initiated	SVB Leerink	Outperform	$29
May-17-21	Resumed	Piper Sandler	Overweight	$47
Nov-10-20	Initiated	Piper Sandler	Overweight	$35
Nov-10-20	Initiated	JP Morgan	Overweight	$33
Nov-10-20	Initiated	Jefferies	Buy	$26
Nov-10-20	Initiated	Cantor Fitzgerald	Overweight	$28

Show Previous Ratings

Jul-13-26 08:00AM	Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection (GlobeNewswire)
Jul-06-26 07:50PM	ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal (Stocktwits)
04:05PM	Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection (GlobeNewswire)
May-27-26 02:30AM	Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 (GlobeNewswire)
May-13-26 02:05AM	Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 (GlobeNewswire)
04:05PM	Loading…
May-07-26 04:05PM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results (GlobeNewswire) -5.34% +6.80%
Apr-30-26 04:05PM	Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-24-26 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-26 06:54AM	Aligos and Xiamen Amoytop sign deal for HBV therapy (Pharmaceutical Technology) -12.79%
Apr-16-26 06:00AM	Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection (GlobeNewswire)
Apr-14-26 04:05PM	Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation (GlobeNewswire) -15.10%
Mar-05-26 08:00AM	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-26-26 08:00AM	Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 (GlobeNewswire) +8.07%
Feb-23-26 08:00AM	Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) (GlobeNewswire)
Jan-30-26 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Jan-21-26 08:00AM	Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates (GlobeNewswire)
Jan-13-26 08:00AM	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer (GlobeNewswire) +6.08%
Dec-12-25 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.51%
Dec-11-25 08:00AM	Aligos Therapeutics Presents Positive Data at HEP-DART 2025 (GlobeNewswire)
Nov-14-25 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.72%
Nov-10-25 08:00AM	Aligos Therapeutics Presents Positive Data at The Liver Meeting 2025 (GlobeNewswire)
Nov-06-25 08:30AM	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:30AM	Aligos Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-30-25 08:30AM	Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-17-25 08:30AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-16-25 08:30AM	Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 (GlobeNewswire)
Oct-14-25 08:30AM	Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference (GlobeNewswire)
Oct-07-25 08:30AM	Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting 2025 (GlobeNewswire)
Sep-08-25 05:04PM	Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect? (Zacks)
Sep-03-25 04:05PM	Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting (GlobeNewswire)
04:05PM	Loading…
Sep-02-25 04:05PM	Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-01-25 12:30PM	Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia (Zacks)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks) +11.19%
Aug-20-25 08:30AM	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramon Polo as Senior Vice President, Head of Global Regulatory Affairs (GlobeNewswire)
Aug-19-25 09:55AM	Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know (Zacks)
Aug-15-25 08:30AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-25 11:11AM	Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
05:51AM	Aligos commences dosing in Phase II trial for chronic hepatitis B treatment (Clinical Trials Arena)
Aug-13-25 08:30AM	Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection (GlobeNewswire)
Aug-06-25 06:00PM	Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-30-25 04:05PM	Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire) -8.20%
Jul-11-25 08:30AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-18-25 08:00AM	Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC) (GlobeNewswire) +11.16%
Jun-13-25 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 08:00AM	Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal (GlobeNewswire)
May-16-25 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-08-25 08:00AM	Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 (GlobeNewswire) +11.70%
May-06-25 09:35AM	Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -9.31%
08:00AM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 09:40AM	UPS downgraded, ServiceNow upgraded: Wall Street's top analyst calls (The Fly) +8.15%
Apr-29-25 08:30AM	Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025 (GlobeNewswire)
Apr-23-25 04:05PM	Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 (GlobeNewswire) +8.77%
Mar-26-25 08:00AM	Aligos Therapeutics Presents Positive Data at APASL 2025 (GlobeNewswire) -10.14%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) +11.28%
08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-10-25 09:25AM	Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -19.55%
08:00AM	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 08:00AM	Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025 (GlobeNewswire) -14.05%
Feb-12-25 07:00AM	Aligos Therapeutics Announces $105 Million Private Placement Financing (GlobeNewswire) -19.25%
Jan-13-25 04:32PM	Here's Why Aligos Therapeutics, Inc. (ALGS) Is Skyrocketing (Insider Monkey) -12.49%
Dec-13-24 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 08:00AM	Aligos Therapeutics to Present at Investor Conferences in December (GlobeNewswire)
Nov-19-24 01:30PM	Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 (GlobeNewswire) -8.05%
Nov-06-24 06:05PM	Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +6.10%
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 04:05PM	Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-22-24 08:00AM	Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 (GlobeNewswire)
Oct-15-24 09:00AM	Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024 (GlobeNewswire)
Oct-11-24 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.60%
Oct-01-24 08:00AM	Aligos Therapeutics Appoints David Perry as Vice President of Business Development (GlobeNewswire)
Sep-30-24 08:00AM	Aligos Therapeutics to Present at Investor Conferences in October (GlobeNewswire) +7.71%
Sep-24-24 08:00AM	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer (GlobeNewswire)
Sep-20-24 04:52AM	Aligos reports positive data from Phase IIa MASH treatment trial (Clinical Trials Arena) -10.22%
Sep-19-24 08:00AM	Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH (GlobeNewswire) -28.11%
Sep-18-24 05:00PM	Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 (GlobeNewswire)
Sep-13-24 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.49%
Sep-10-24 09:40AM	Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year? (Zacks) -29.03%
Aug-21-24 09:55AM	How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% (Zacks) -5.04%
Aug-15-24 09:00AM	Aligos Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Aug-09-24 12:00PM	What Makes Aligos Therapeutics (ALGS) a New Buy Stock (Zacks)
Aug-08-24 04:05PM	Aligos Therapeutics Strengthens Board with Two New Independent Directors (GlobeNewswire)
Aug-07-24 12:53PM	Hepatitis B market is ripe for treatment development, says Aligos CEO (Pharmaceutical Technology) +21.95%
Aug-06-24 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 04:05PM	Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-22-24 09:00AM	Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. (GlobeNewswire) +11.08%
Jul-10-24 08:00AM	Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB (GlobeNewswire) +7.89%
Jun-05-24 02:30AM	Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 (GlobeNewswire)
Jun-04-24 09:55AM	Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now (Zacks)
May-22-24 04:05PM	Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 (GlobeNewswire) -8.95%
May-21-24 08:00AM	Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH (GlobeNewswire)
May-16-24 09:35AM	After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS) (Zacks)
May-07-24 09:56PM	ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 04:05PM	Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-25-24 04:05PM	Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study (GlobeNewswire)
08:00AM	Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD (GlobeNewswire)
Apr-09-24 08:00AM	Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects (GlobeNewswire)

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Ph.D.Dr. Lawrence M. Blatt MBA

Executive VPMs. Lesley Ann Calhoun CPA

Executive VP & Chief Scientific OfficerDr. Julian A. Symons DPHIL

Principal Accounting OfficerMr. Nikhil Aneja

VP & Head of LegalMs. Laura Kavanaugh

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALGS

Aligos Therapeutics Inc

Upgrade your Finviz experience